Showing 1 - 10 results of 10 for search 'Alfons A den Broeder', query time: 0.03s
Refine Results
-
1
-
2
PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial by Diane E. Marsman, Thomas E. Bolhuis, Nathan den Broeder, Alfons A. den Broeder, Aatke van der Maas
Published 2022-04-01
Article -
3
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Final... by Iris Rose Peeters, Alfons A. den Broeder, William J Taylor, Nathan den Broeder, Marcel Flendrie, Noortje van Herwaarden
Published 2023-04-01
Article -
4
-
5
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis by Daniel Aletaha, Alfons A den Broeder, Paco M J Welsing, Janneke Tekstra, P Verschueren, Marianne A Messelink, Florine E Marinelli, Edwin Michgels
Published 2023-04-01
Article -
6
-
7
Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study) by Céleste J.T. van der Togt, Lise M. Verhoef, Bart J.F. van den Bemt, Nathan den Broeder, Rob ter Heine, Alfons A. den Broeder
Published 2022-12-01
Article -
8
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial by Nathan den Broeder, Aatke van der Maas, Alfons A den Broeder, Bart JF van den Bemt, Frank HJ van den Hoogen, Yael A de Man, Marc R Kok, Lise Verhoef, Rogier Thurlings, Wilfred van der Weele
Published 2024-04-01
Article -
9
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi s... by Daniel Aletaha, Katerina Chatzidionysiou, Alfons A den Broeder, Paco M J Welsing, Rieke Alten, Bart van den Bemt, Denis Mulleman, James Galloway, John Isaac, P Verschueren, Arnold G Vulto, Céleste J T van der Togt, Lise Verhoef
Published 2023-03-01
Article -
10
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the... by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Published 2022-07-01
Article